-
-
-
-
-
-
-
RBC Capital: 'On balance we think readthroughs from the GSK acquisition of NUVB's key competitor are positive'
-
-
-
-
-
-
-
Truist Securities on Nuvation Bio Inc (NUVB): safusidenib opportunity 'represents meaningful upside'
-
-
-
-
-
-
-
Nuvation Bio reports $24.7 million in revenue for cancer drug IBTROZI
-
-
-
-
-
-
-
Jefferies Starts Nuvation Bio Inc (NUVB) at Buy
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Nuvation Bio Inc (NUVB)
-
-
-
-
-
-
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
-
-
-
-
-
-
BTIG Upgrades Nuvation Bio Inc (NUVB) to Buy, has 'two potentially best-in-class drugs'
-
68,259 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

